停药，即在个体患者的护理背景下，悬停已经或潜在的危害大于益处的药物，是当今各种会议中越来越常见的话题。这个问题尤其在预期寿命不到一年的慢性病患者中突出，其中治疗目标从康复转向关怀。目前有少量经过验证的停药工具，其中之一就是STOPPFrail，目前已有第二个版本可用。因此，我们决定进行意大利语翻译，以使老年患者的有限寿命期望的描述更具适用性。对于翻译，我们采用欧洲癌症研究与治疗组织（Eortc）所提出的前后翻译方法和试点测试来验证翻译本身的清晰度和可理解性。我们采访了15位专家，其中13位回答并完成了评估，没有发现任何不清楚部分或误解的来源。STOPPFrail2可以成为老年有限寿命期望者的有效停药工具；意大利语版本可以帮助医生在这个需要关注生活质量和选择伦理方面的生命阶段中进行治疗的适宜性，同时也在“成本机会”逻辑中提供帮助。

Deprescribing, i.e. the suspension of drugs whose existing or potential harms outweigh the benefits in the context of care for the individual patient, is an increasingly frequently encountered topic in various congresses today. This issue becomes predominant especially in patients with chronic pathologies with a life expectancy of less than a year, in whom the goal of the treatments passes from healing to caring. Currently there are few validated deprescribing tools, one of these is certainly the STOPPFrail, currently available in its second version. Therefore, we decided to provide for the translation into Italian, to make the description for the elderly patient with limited life expectation more applicable.For the translation, we used the method expressed by the European organisation for research and treatment of cancer (Eortc), using forward-backward translation and a Pilot Testing to verify the clarity and comprehensibility of the translation itself.We interviewed 15 experts, of whom 13 responded and completed the evaluation, without bringing to light any unclear sections or sources of misunderstanding.STOPPFrail2 can be a valid deprescribing tool in the elderly with limited life expectancy; the Italian version can help the physicians in the therapeutic appropriateness in this time of life where it is necessary to focus on the quality of life and on the ethical aspect of the choices, as well as being of help in a "cost-opportunity" logic.